| dbo:abstract
|
- The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science.Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is (Germany), and previous Chairs have been (U.K.), Wayne Hendrickson (U.S.A.), (Switzerland) and (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current (March 2022) Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda. SGC research activities take place in a coordinated network of university-affiliated laboratories – at Goethe University Frankfurt, Karolinska Institutet, McGill University, and the Universities of North Carolina at Chapel Hill and Toronto. The research activities are supported both by funds from the SGC Company as well as by grants secured by the scientists affiliated with the SGC programs. At each university, the scientific teams are led by a Chief Scientist, who are (Goethe University Frankfurt), (Karolinska Institutet), (McGill University), (University of North Carolina at Chapel Hill), and Cheryl Arrowsmith (University of Toronto). The SGC currently comprises ~200 scientists. (en)
- Structural Genomics Consortium (SGC) är ett icke vinstinriktat konsortium som bildades 2004 för att bestämma tre-dimensionella strukturer av proteiner som har medicinsk relevans och deponera dem i Protein Data Bank utan restriktioner. SGC har aktiviteter på universiteten i Oxford och Toronto samt Karolinska Institutet i Stockholm och finansieras av , GSK, Novartis, Merck, Knut och Alice Wallenbergs Stiftelse, Vinnova och Stiftelsen för Strategisk Forskning. Sedan starten har SGC deponerat över 800 proteinstrukturer från den lista av ~2,000 proteiner man i första hand inriktat sig på. Denna lista innehåller proteiner som i första hand har relevans för människans hälsa och sjukdomar, som till exempel proteiner associerade med diabetes, cancer och infektionssjukdomar som malaria. SGC koncentrerar sin verksamhet till vissa proteinfamiljer såsom, dehydrogenaser, kinaser, 14-3-3 proteiner, ATPaser, RNA helicaser, protein tyrosin phosphataser, sulfotransferaser, poly-(adp-ribose)-polymeraser, histone demethylaser och methyltransferaser. SGC är ett "open access" partnerskap mellan myndigheter, akademien och industrin - en ny modell för hur läkemedelsforskning kan bedrivas icke-kompetitivt för att generera potenta och selektiva farmakologiska inhibitorer eller aktivatorer av humana proteiner. Dessa reagens kommer att ställas till förfogande för all användning utan restriktioner. (sv)
|
| rdfs:comment
|
- The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science.Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current (en)
- Structural Genomics Consortium (SGC) är ett icke vinstinriktat konsortium som bildades 2004 för att bestämma tre-dimensionella strukturer av proteiner som har medicinsk relevans och deponera dem i Protein Data Bank utan restriktioner. SGC har aktiviteter på universiteten i Oxford och Toronto samt Karolinska Institutet i Stockholm och finansieras av , GSK, Novartis, Merck, Knut och Alice Wallenbergs Stiftelse, Vinnova och Stiftelsen för Strategisk Forskning. (sv)
|
